In part 2 of this conversation, Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses the guidance and how it will affect sponsors moving forward.
ACT: What are your thoughts on the FDA’s recently released Diversity Action Plan Guidance? How will this affect sponsors moving forward?
Moultrie: I am a strong proponent for what gets measured gets done, so I strongly believe having the industry guidance—once finalized and put into action—it'll require a level of accountability that I think a lot of folks may have been working towards or figuring out, but having that requirement makes it real. I think it sets a precedent for what has to happen, and I think folks will start moving more intently towards those goals. It's when somethings are nice to have versus when it's a must have—I think we move differently, we allocate resources differently, we discuss planning, and things like that a bit differently when things are required. That requirement piece, I think, is necessary, and we've seen the shift already with just the guidance coming—the ways in which things are changing. Once the guidance of finalized and it's moved out, I think that that change and that shift is going to happen much more robustly.
I think for our sponsor partners, one of the biggest things to consider is how it's going to affect implementation. We may have to adjust how we handle timelines and how we set these goals, there may likely be more time spent up front and figuring out of how to disseminate and when we're going to do trial selection, where are we going to place these trials, who are the investigators are going to look at? But again, that level of accountability, I think, is going to force a lot of us, and not just sponsors and CROs, at the site side as well, to do things a bit differently and consider things a bit differently and prepare differently so that we can meet those goals.
Empowering Sites and Patients: The Impact of Personalized Support in Clinical Trials
November 26th 2024To meet the growing demands of clinical research, sponsors must prioritize comprehensive support models, such as clinical site ambassadors and patient journey coordinators, who can address operational challenges and improve site relationships, patient satisfaction, and overall trial efficiency.
FDA Finalizes Decentralized Clinical Trial Guidance
November 25th 2024The FDA's guidance is part of a broader effort to modernize clinical trials, improve efficiency, reduce participant burden, and expand access, particularly for underrepresented populations and those in geographically or economically constrained areas.
In Focus: Addressing the Health Literacy Roadblock in Patient Recruitment
Published: November 15th 2024 | Updated: November 15th 2024With universal adoption of health literacy best practices slow going over the years, advocates are redefining the term to encompass much more of what health-related communication requires beyond simply words.